Cookson Peirce & Co. Inc. Raises Position in Medpace Holdings, Inc. $MEDP

Cookson Peirce & Co. Inc. raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 508.0% during the 4th quarter, HoldingsChannel reports. The fund owned 2,900 shares of the company’s stock after acquiring an additional 2,423 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Medpace were worth $1,629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Optiver Holding B.V. purchased a new position in shares of Medpace during the 3rd quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace during the 4th quarter worth $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace during the 4th quarter worth $30,000. Quarry LP purchased a new position in shares of Medpace during the 3rd quarter worth $35,000. Finally, Core Wealth Advisors LLC purchased a new position in shares of Medpace during the 4th quarter worth $47,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP opened at $454.25 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $294.07 and a fifty-two week high of $628.92. The firm’s fifty day moving average is $456.73 and its 200 day moving average is $508.39. The stock has a market cap of $12.97 billion, a price-to-earnings ratio of 28.55, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the previous year, the company earned $3.67 EPS. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MEDP shares. Leerink Partners dropped their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday, February 13th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and dropped their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Truist Financial lowered their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $467.08.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.